Sector Rotation: Fidelity Select Biotechnology Fund

Fidelity Select Biotechnology Fund (FBIOX, last change: 2.07%)

The Fidelity Select Biotechnology Fund (FBIOX, last change: 2.07%) has made a new 52-week high yesterday. After the May correction the biotech sector stabilized in mid June, which was followed by a new market rally. In our view, FBIOX is one of the best biotech  funds available to investors, so we are not surprised that it outperformed other biotech mutual funds and ETFs during the recent volatile period.

Buy/sell signals for Fidelity funds are available at FidelitySignal.com 

Breakout: the technology and the consumer discretionary/retailing sectors are emerging as the market leaders

The beginning of the earnings season has brought about an impressive stock market rally. Improved sentiment in Europe was also helpful. The fact that all Fidelity sector funds gained today is an indicator of how broad-based the buying was.

The technology sector is providing leadership to the market, as so many times in the last 20 years, with multiple companies reporting strong earnings results. The United States is the undisputed world leader in technology innovation and companies like Google, Apple, Amazon and eBay continue to reward their shareholders with growth.

In addition to the large cap tech companies, a large number of medium and small sized companies are developing breakthrough technologies promising to make our lives more efficient, safer and more enjoyable. We will continue to keep an  eye on investment opportunities in the technology sector.

Fidelity Select Software & Comp fund (FSCSX, change: 2.10%)

Fidelity Select Software & Comp fund (FSCSX, change: 2.10%)

Consumer discretionary and retailing stocks are also responding to the increased appetite to buy equities and can provide leadership to the market in the coming weeks.

Fidelity Select Retailing fund (FSRPX, change: 1.85%)

Fidelity Select Retailing fund (FSRPX, change: 1.85%)

Mutual fund screens are provided by FidelitySignal.com